Table 2.
Baseline characteristics of patients
| Variable | Before matching | After matching | ||||
|---|---|---|---|---|---|---|
| LR (n = 701) | TACE (n = 1034) | P value | LR (n = 623) | TACE (n = 623) | P value | |
| Age, y | 51 (22‐75) | 54 (23‐75) | 0.100 | 51 (23‐75) | 51 (23‐75) | 0.898 |
| Sex(M/F) | 652/49 | 963/71 | 0.921 | 590/33 | 588/35 | 0.901 |
| Hepatitis B (±) | 645/56 | 950/84 | 0.919 | 601/22 | 601/22 | 0.999 |
| Hepatitis C (±) | 21/680 | 26/1008 | 0.545 | 16/607 | 13/610 | 0.708 |
| Cirrhosis(yes/no) | 617/84 | 889/145 | 0.218 | 599/24 | 595/28 | 0.671 |
| Child Pugh classification (A/B) | 689/12 | 1001/33 | 0.057 | 615/8 | 615/8 | 0.999 |
| ECOG status (0/1) | 658/43 | 960/74 | 0.436 | 601/22 | 598/25 | 0.767 |
| Portal hypertension (yes/no) | 182/519 | 291/743 | 0.323 | 165/458 | 156/467 | 0.604 |
| R15, % | 0.068 | 0.810 | ||||
| ≤10 | 645 | 924 | 585 | 588 | ||
| >10 | 56 | 110 | 38 | 35 | ||
| Tumor size, cm | 0.168 | 0.818 | ||||
| ≤5 | 266 | 358 | 265 | 260 | ||
| >5 | 435 | 676 | 358 | 363 | ||
| Tumor number | 0.127 | 0.999 | ||||
| 2 | 331 | 449 | 330 | 330 | ||
| >2 | 370 | 585 | 293 | 293 | ||
| AFP, ng/mL | 0.159 | 0.894 | ||||
| ≤400 | 170 | 221 | 150 | 147 | ||
| >400 | 531 | 813 | 473 | 476 | ||
| GGT, u/L | 430.2 (33.5‐690.1) | 456.2 (25.1‐622.7) | 0.512 | 430.0 (33.5‐622.7) | 431.0 (33.1‐622.7) | 0.870 |
| ALT, u/L | 25.5 (13.0‐66.0) | 28.2 (11.0‐74.8) | 0.154 | 26.5 (13.0‐66.0) | 26.5 (13.0‐65.3) | 0.914 |
| Albumin, g/L | 36.3 (34.8‐42.5) | 35.9 (34.0‐47.3) | 0.251 | 35.5 (34.9‐42.5) | 35.5 (34.8‐42.5) | 0.900 |
| TBIL, umol/L | 11.4 (6.3‐28.5) | 12.5 (5.5‐34.2) | 0.311 | 11.6 (6.5‐28.5) | 11.7 (6.7‐28.5) | 0.943 |
| Creatinine, umol/L | 67.5 (38.7‐99.5) | 70.3 (47.8‐95.0) | 0.685 | 68.9 (48.8‐94.5) | 68.9 (48.8‐95.0) | 0.889 |
| Platelet count, 109/L | 121.2 (92.0‐320.0) | 118.5 (75‐345) | 0.096 | 119.0 (92.0‐320.0) | 119.0 (92.0‐320.0) | 0.980 |
| Hemoglobin, g/L | 126.0 (112.0‐150.0) | 124.0 (105.0‐153.0) | 0.647 | 125.0 (113.0‐149.0) | 125.0 (114.0‐149.0) | 0.923 |
| White blood cell, 109/L | 5.5 (4.5‐8.0) | 5.8 (4.3‐9.0) | 0.185 | 5.6 (4.6‐8.0) | 5.6 (4.6‐8.0) | 0.899 |
| Distribution of tumor | 0.977 | 0.999 | ||||
| Right liver | 412 | 607 | 405 | 405 | ||
| Left liver | 41 | 62 | 36 | 36 | ||
| Both liver | 248 | 365 | 182 | 182 | ||
| Follow‐up time (median, months) | 32.0 (1‐96) | 31.0 (1‐96) | 0.982 | 32.0 (1‐96) | 32.0 (1‐96) | 0.996 |
There was no significant difference in average age between LR (51 years) and TACE (54 years) groups. Hepatitis B virus infection was the major etiology of HCC while Hepatitis C virus was the minor one. Most of the patients have developed cirrhosis and cirrhotic patients were mainly in the classification of Child‐pugh A.
LR, liver resection; TACE, transarterial chemoembolization; GGT, γ‐glutamyltranspeptidase; ALT, alanine amino transferase; TBIL, total bilirubin; ICGR15, indocyanine green retention rate in 15 minutes; AFP, alpha‐fetoprotein; ECOG, Eastern Cooperative Oncology Group.